Compare AdaptHealth Corp (AHCO) vs Nuscale Power Corporation (SMR) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

NuScale Power (SMR) trades at $9.61, down 1.54% on the day, reflecting ongoing bearish technical momentum. The company shows severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61 million in 2025. Despite this, analyst consensus remains optimistic with a $13.00 price target, and recent news highlights potential long-term growth from SMR technology commercialization and partnerships like ENTRA1.

The outlook is highly speculative; significant upside exists if NuScale successfully commercializes its reactors by the 2030s, but near-term risks include persistent losses, high cash burn, and execution hurdles. Investors face substantial volatility with the stock near its 52-week low, requiring high risk tolerance for potential multi-bagger returns amid operational and competitive challenges.